Claims for Patent: 7,442,389

Summary for Patent: 7,442,389

Title:	Methods of administering microparticles combined with autologous body components
Abstract:	Microspheres to be implanted into a patient are metered and mixed with fluids, cells, or tissues withdrawn from the patient\'s own body, and reinserted into the patient\'s body to achieve augmentation, repair or other treatment of the patient\'s tissue.
Inventor(s):	Quelle; Gerhard (Wald-Michelbach, DE), Anderson; Russell J. (San Diego, CA), Lemperle; Stefan M. (San Diego, CA)
Assignee:	Artes Medical, Inc. (San Diego, CA)
Application Number:	11/210,273
Patent Claims:	1. A tissue treatment implant for administration to a patient, comprising: a bulking agent consisting of a plurality of round and smooth polymethylmethacrylate microparticles preloaded within a mixing and delivery system; and an autologous carrier made from cells obtained from soft tissue withdrawn from said patient into the mixing and delivery system; wherein the bulking agent and the autologous carrier are combined within the mixing and delivery system and then delivered to the treatment location. 2. The tissue treatment implant of claim 1, wherein the autologous carrier contacts at least a portion of the plurality of round and smooth polymethylmethacrylate microparticles. 3. The tissue treatment implant of claim 1, wherein the autologous carrier contacts substantially all of the plurality of round and smooth polymethylmethacrylate microparticles. 4. The tissue treatment implant of claim 1, wherein the autologous carrier is mixed with the plurality of microparticles. 5. The tissue treatment implant of claim 1, wherein the autologous carrier comprises bodily tissue withdrawn from the patient's connective tissue. 6. The tissue treatment implant as set forth in claim 1, wherein the autologous carrier comprises one or more of adipose tissue, a component of adipose tissue, and combinations thereof. 7. The tissue treatment implant as set forth in claim 6, wherein the adipose tissue is derived from one or more of subcutaneous fat, loose or flaccid body fat, and combinations thereof. 8. The tissue treatment implant as set forth in claim 1, wherein the adipose tissue is derived from one or more of fat around the patient's waistline, a component of the fat, and combinations thereof. 9. The tissue treatment implant as set forth in claim 1, wherein the autologous carrier comprises one or more of marrow, a component of marrow, and combinations thereof. 10. The tissue treatment implant as set forth in claim 1, wherein the autologous carrier comprises one or more of fibrous tissue, a component of fibrous tissue, and combinations thereof. 11. The tissue treatment implant as set forth in claim 1, wherein the autologous carrier comprises one or more of muscle tissue, a component of muscle tissue, and combinations thereof. 12. The tissue treatment implant as set forth in claim 1, wherein the autologous carrier comprises one or more of cartilage tissue, a component of cartilage tissue, and combinations thereof. 13. The tissue treatment implant as set forth in claim 12, wherein the cartilage tissue is derived from one or more of ear tissue, ribs tissue, and knee tissue. 14. The tissue treatment implant as set forth in claim 1, wherein the autologous carrier comprises cells of dermal tissue. 15. The tissue treatment implant as set forth in claim 1, wherein the autologous carrier comprises cells of mucosa. 16. The tissue treatment implant as set forth in claim 1, wherein the autologous carrier comprises one or more of cells of the patient in any ration, a component of the cells, and combinations thereof. 17. The tissue treatment implant as set forth in claim 1, wherein the autologous carrier comprises one or more of stem cells of the patient in any ration, a component of the stem cells, and combinations thereof. 18. The tissue treatment implant as set forth in claim 1, wherein the autologous carrier comprises cells of one or more of (a) connective tissue, (b) adipose tissue, (c) marrow, (d) fibrous tissue, (e) muscle tissue, (f) cartilage tissue, (g) dermal tissue, (h) mucosa, and (i) combinations thereof. 19. The tissue treatment implant as set forth in claim 1, wherein: the microparticles possess one or more of (a) sizes between about 10 microns and about 500 microns, (b) smooth surfaces free from corners, edges, peaks and projections, (c) at least one of elliptical, cylindrical, and spherical forms, and (d) one or more of smoothed or rounded corners, edges, peaks, and projections; and the microparticles comprise one or more of a porous surface, a porous body, a shell-like structure, a hollow interior, a metallic coating, a carbon coating, a carbon nanotube coating, components thereof, and combinations thereof in any ratio. 20. The tissue treatment implant as set forth in claim 1, wherein the microparticles have a short-term effectiveness of up to about 6 months, and comprise one or more of collagen; hyaluronic acid; and genetically altered cells, tissues or microorganisms. 21. The tissue treatment implant as set forth in claim 1, wherein the microparticles have a medium-term effectiveness of up to about 3 years, and comprise one or more of collagen; hyaluronic acid; and genetically altered cells, tissues or microorganisms. 22. The tissue treatment implant as set forth in claim 1, wherein the microparticles have a long-term effectiveness of more than about 3 years, and comprise any type of collagen, hyaluronic acid; and genetically altered cells, tissues or microorganisms. 23. The tissue treatment implant as set forth in claim 1, wherein the microparticles comprise one or more of polylactic acid, a ceramic material, polymethacrylate, polymethylmethacrylate (PMMA), polypropylene, or polytetrafluoroethylene (PTFE). 24. The tissue treatment implant as set forth in claim 1, wherein the microparticles have a long-term effectiveness of more than about 3 years, and comprise purified cytoskeleton of unicellular or multicellular algae. 25. The tissue treatment implant as set forth in claim 1, wherein the microparticles comprise two or more of collagen, hyaluronic acid, polylactic acid, ceramic materials, polymethacrylate, polymethylmethacrylate (PMMA), polypropylene, polytetrafluoroethylene (PTFE), and purified algae cytoskeleton. 26. The tissue treatment implant of claim 1, wherein the round and smooth polymethylmethacrylate microparticles are sterile. 27. The tissue treatment implant of claim 1, further comprising one or more of sterile water, an aqueous isotonic solution of saline, an aqueous isotonic solution of phosphate salts, a hypertonic aqueous solution, a hypotonic solution, a component thereof, and combinations thereof. 28. The tissue treatment implant of claim 1, further comprising a sterile aqueous thickening agent. 29. The tissue treatment implant of claim 28, wherein the sterile aqueous thickening agent comprises one or more of collagen, gelatin, hyaluronic acid, methyl-cellulose, polylactic acid, a component thereof, and combinations thereof. 30. The tissue treatment implant of claim 1, wherein the tissue treatment implant is disposed within an aspiration syringe. 31. The tissue treatment implant of claim 1, wherein the tissue treatment implant is disposed within a metered aspiration, mixing and delivery system. 32. The tissue treatment implant of claim 31, wherein the metered aspiration, mixing and delivery system comprises a rotatable metering sleeve. 33. The tissue treatment implant of claim 31, wherein the metered aspiration, mixing and delivery system further comprises a micronizing device. 34. The tissue treatment implant of claim 33, wherein the micronizing device comprises one or more of structure configured to perform physical micronization, structure configured to perform ultrasonic micronization, a component of either, and combinations thereof. 35. The tissue treatment implant of claim 1, further comprising an agent to assist in homogeneity. 36. The tissue treatment implant of claim 1, further comprising a coagulant agent. 37. The tissue treatment implant of claim 1, further comprising an agent to facilitate bonding. 38. The tissue treatment implant of claim 1, further comprising an adhesion prevention agent. 39. The tissue treatment implant of claim 1, further comprising an antibiotic agent. 40. The tissue treatment implant of claim 1, further comprising an anesthetic agent. 41. The tissue treatment implant of claim 1, wherein the microparticles have a long-term effectiveness of more than about 3 years.

Details for Patent 7,442,389

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2024-08-20